Fig. 5. Role of ApoE in CCHFV infection.
a–c, Level of infection in SW13 infected with VSV-CCHF (a), CCHFV IbAr10200 (b) and CCHFV isolate (c) treated with decoy receptor LRP8 (MOI 0.01, 6 h.p.i. or 24 h.p.i.). Data are mean ± s.d. of n = 3 independent experiments. P values were calculated using one-way ANOVA. d–g, Neutralization assay of VSV-CCHF produced on HEK293 cells (d), CCHFV IbAr10200 produced on SW13 cells (e), CCHFV produced on HepG2 cells (f) and CCHFV produced on HepG2 ApoE KO cells (g) using a neutralizing anti-ApoE antibody (MOI 0.01, 6 h.p.i. or 24 h.p.i.). Data are mean ± s.d. of n = 3 independent experiments. P values were calculated using two-tailed Student’s t-test. *P < 0.05, **P < 0.01; ***P < 0.001; ****P < 0.0001. NS P > 0.05. Exact P values are available in.